You are here


2021 Technology Showcase

Primary tabs

2021 Technology Showcase National Cancer Institute and Frederick National Laboratory

Thank you for another great event! 

Thank you!


If you are interested in learning more about any of the technologies presented, would like a copy of poster or a presentation, or would like to connect with NCI or FNL, please reach out. or FNL -


  • Free, half-day virtual event.
  • Hear from inventors from the National Cancer Institute and the Frederick National Laboratory  about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders and companies of all sizes, including start-ups.
  • Panel sessions focused on technology commercialization.
  • Lightning Pitch & Poster Session highlighting additional NIH technologies available for licensing and collaborative development presented by the NCI Technology Transfer Ambassadors Program.

DATE & TIME: Wednesday, September 1, 2021
11:45 am - 5:15 pm EST

ENGAGE with fellow attendees:

Join our LinkedIn Event, Follow #CancerTechShow21, September 1, 2021


11:45 am - Join online

Noon - 12:30 pm - Keynote presentations

Mark Stewart. Ph.D.
Vice President of Science Policy
Friends of Cancer Research (Friends)



Dr. Mark Stewart, Vice President of Science Policy, Friends of Cancer Research

James Cherry, Ph.D.
NIAID, Chief, Research Technologies Branch, on detail as NCI Scientific Program Director (SeroNet)

Dr, James Cherry, NCI Spotlight on Scientists video link

12:30 - 1:20 pm - Technology Presentations, Session 1

NCI and FNL technology presenters 

1. Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, CCR, NCI
Technology: "Single Domain Antibodies Targeting SARS-CoV-2 for treating COVID-19" (E-253-2020)

2. Rosandra Kaplan, M.D., Head, Tumor Microenvironment and Metastasis Section, CCR, NCI
Technology: "Genetically Engineered Myeloid Cells as a Platform to Reprogram Diseased Microenvironments" (E-053-2019)

3. Stavroula Mili, Ph.D., Stadtman Investigator, Laboratory of Cellular and Molecular Biology, NCI
Technology: "Antisense Oligonucleotides against Cancer Cell Migration and Invasion" (E-041-2020)  

4. Eric Stahlberg, Ph.D., Director, Biomedical Informatics and Data Science Directorate, FNL
ATOM: Democratizing Drug Discovery”

5. Howard Young, Ph.D., Senior Investigator, Laboratory of Cancer Immunometabolism, CCR, NCI
Technology: "The ARE-Del mouse: A novel model for autoimmunity"

1:30 - 2:30 pm - Panel Sessions 1 & 2

Attendee selects one of two concurrent panel sessions

Panel 1: “How collaborators can tap into laboratory resources at the Frederick National Laboratory”
Moderator: Claudia Haywood, J.D., Director of Intellectual Property and Strategic Agreements, Frederick National Laboratory (FNL)
Rachael Crist, Ph.D. -  Head of Strategic Client Relations, Nanotechnology Characterization Laboratory, DCTD, FNL, NCI
Serguei Kozlov, Ph.D., MBA – Center for Advanced Preclinical Research, FNL, NCI
Jana Ognjenovic, Ph.D. – Scientist, National Cryo-EM Facility, FNL

Panel 2: “Foundations and philanthropies as strategic partners”
Moderator: Jamie Troil Goldfarb, cancer survivor and patient advocate, Melanoma Research Alliance (MRA)
Joan Levy, Ph.D., Senior Director of Special Projects, MRA
Sujuan Ba, Ph.D., President and CEO, National Foundation for Cancer Research    
Ashley Calabrese, MBA Director, Alliance Management, Multiple Myeloma Research Foundation (MMRF)

2:30 - 3:25 pm
Technology Transfer Ambassadors Program, Lightning Pitch & Poster Session

Presenters will each deliver a one-minute "lightning pitch." Attendees can then opt to learn more by joining one of the four break-out rooms.
In the breakout rooms, presenters will share a poster about their selected technology and provide a short (five-minute) presentation.
Attendees will be able to ask the poster presenters questions and move between breakout rooms.


Moderator: Laura Prestia, Ph.D., NCI Technology Transfer Center (TTC), Communications and Strategic Initiatives Manager, TTAP Program Lead


Moderator: Laura Prestia, Ph.D.

Presented by: Sabina Kaczanowska, Ph.D.,Transition to Industry Fellow and Inventor
Inventor: Rosandra Kaplan, M.D., NCI CCR Pediatric Oncology Branch
"Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Anti-Tumor Immunity" (E-053-2019)
Presented by: Eric Chun Hei Ho, Ph.D., Transition to Industry Fellow and Inventor
Inventor: David FitzGerald, Ph.D., NCI CCR Laboratory of Molecular Biology
"EGFRvIII Antibodies for the Treatment of Human Cancer" (E-103-2019)
Presented by: Snehal Gaikwad, Ph.D., TTAP Ambassador and Transition to Industry Fellow
Inventors: John 'Jay' Schneekloth Jr., Ph.D., NCI CCR Chemical Biology Laboratory, Beverly Mock, Ph.D., NCI, CCR, Laboratory of Cancer Biology and Genetics
"Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex" (E-053-2015)

Moderator: Abritee Dhal, Ph.D., NCI TTC Technology Transfer Manager & TTAP Team Lead

Presenter: Berna Uygur, Ph.D., TTC Fellow
Inventor: Zhengping Zhuang, M.D. Ph.D., NCI CCR Neuro-Oncology Branch
"Use of the TP5 Peptide for the Treatment of Cancer" (E-007-2019)
Presented by: Nick Cilz, Ph.D., TTC Fellow
Inventor: Joel Morris, Ph.D., NCI Division of Cancer Treatment and Diagnosis (DCTD), Drug Synthesis and Chemistry Branch
"Efficacious Fluorinated Cytidine Analog Cancer Therapeutic With Low Toxicity In Animal Studies" (E-215-2018)
Presenter: Gandhy Pierre-Louis, TTC Fellow
Inventor: Xin Wei Wang, Ph.D., NCI CCR Laboratory of Human Carcinogenesis
"A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma" (E-174-2019)

Moderator: Rose Freel, Ph.D., NCI TTC, Senior Technology Transfer Manager & TTAP Team Lead

Presented by: Diptadip Dattaroy, Ph.D., TTC Fellow
Inventor: Kyung Lee, Ph.D., NCI CCR Laboratory of Metabolism 
"New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer" ( E-211-2020)
Presented by: James Kirui, Ph.D., TTAP Ambassador
Inventor: Lawrence Samelson, M.D., NCI CCR Laboratory of Cellular and Molecular Biology
"Chimeric Adaptor Proteins (CAPs) for Use in T Cell-Based Immunotherapy" (E-210-2018)
Presented by: Wing-Hang Tong, Ph.D., TTAP Ambassador
Inventor: Crystal Mackall, M.D., Stanford Cancer Institute, formerly NCI CCR Pediatric Oncology Branch
"Chimeric Antigen Receptors to CD276 for Treating Cancer" (E-243-2015)
Presented by Harmen Steele, Ph.D., TTC Fellow
Inventor: Brad St. Croix, Ph.D., NCI CCR, Mouse Cancer Genetics Program
"Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276" (E-145-2019)

Moderator: Suna Gulay French, Ph.D., NCI TTC Technology Transfer Manager & TTAP Team Lead

Presented by: Michaela McCrary, Ph.D., TTC Fellow 
Inventor: Yves Pommier, M.D., Ph.D., NCI CCR Developmental Therapeutics Branch
"Synergistic Use of Exo VII Inhibitors and Quinolone Antibiotics for Treating Bacterial Infection" (E-171-2020)
Presented by: Jonathan Motley, Ph.D., TTC Fellow 
Inventor: Beverly Mock, Ph.D., NCI CCR Laboratory of Cancer Biology and Genetics
"Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy" (E-013-2012)
Presenter: Daniela Lecca, Ph.D., Research and Entrepreneurial Training Immersion (RETI) Fellow, National Institute on Aging (NIA)
Inventor: Nigel Greig, Ph.D., NIA Translational Gerontology Branch
"Phenserine Tartrate: A Therapeutic Treatment for Neurodegenerative Disorders" 
Presented by: Nate Whitman, Ph.D., TTC Fellow
Inventor: Josephine Egan, M.D., NIA Laboratory of Clinical Investigation
"Human Insulin C-Alpha-Peptides and Methods of Use" (E-062-2021)

3:30 - 4:20pm - Technology Presentations, Session 2

6. Jay Berzofsky, M.D., Ph.D., Chief, Vaccine Branch, Center for Cancer Research (CCR), NCI
Presentation: "COVID19 mucosal vaccine studies in rhesus macaques"

7. James Hodge, Ph.D., MBA, Senior Investigator, Laboratory of Tumor Immunology and Biology, CCR, NCI  
Technology: "Combination Therapy for Prostate and Breast Cancer" (E-257-2014)

8. Omar Lopez, Ph.D., presenting on behalf of Joel Morris, Ph.D., Chief, Drug Synthesis and Chemistry Branch, Division of Cancer Treatment and Diagnosis, NCI
Technology: "Efficacious Fluorinated Cytidine Analog Cancer Therapeutic With Low Toxicity in Animal Studies" (E-215-2018)

9. Stephan Stern, Ph.D., DABT, Laboratory Co-Director, Director of Research & Development, Nanotechnology Characterization Laboratory, Division of Cancer Treatment & Diagnosis (DCTD), NCI
Technology: "Polymeric Delivery Platform for Therapeutics" (E-097-2017)

4:25 - 5:15 pm - Panel Sessions 3 & 4

Attendee selects one of two concurrent panel sessions

Panel 3: “How to work with the National Cancer Institute and the Frederick National Laboratory”  
Moderator: Steve Ferguson, NIH Office of Technology Transfer
James Hodge, Ph.D., MBA, NCI CCR, Laboratory of Tumor Immunology and Biology  
Helen Sabzevari, Ph.D., President & CEO, Precigen
Michael Pollack, Ph.D., Unit Supervisor, NCI TTC
Maggie Scully, Ph.D., Senior Business Development Analyst, FNL Partnership Development Office 

Panel 4: “Funding and resources for startups”
Moderator: Richard Griffin
, AICP, CEcD, Director of Economic Development, City of Frederick  
William Bozza, Ph.D.
, Program Director, NCI SBIR & SBIR-TT  
Matthew Miessau, Associate, Epidarex Capital
Kimberly Mozingo, Director of Federal Programs, TEDCO 
Helen Propheter, Executive Director, Economic and Workforce Development, Frederick County Office of Economic Development



Monday, March 22, 2021
Wednesday, September 1, 2021